EHMT2 and early-onset autosomal dominant Alzheimer disease: In the study of the pharmacological mechanism of G9a/GLP on early-onset Alzheimer’s disease in rat, inhibition of G9a/GLP complex could increase the levels of synaptophysin, nerve growth factor (NGF) and BDNF in brain tissues, showing a significant neuroprotective effect on rats [13].